GARDASIL Vaccine Impact in Population Study.

Trial Profile

GARDASIL Vaccine Impact in Population Study.

Phase of Trial: Phase IV

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Female genital diseases; Human papillomavirus infections; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Acronyms VIP
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Dec 2015 Change in Time Frame after Gardasil licensure:- changed from 2011-2012 to 2007-2011. Patient ages also specifically mentioned in the timepoints as per record.
    • 01 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by record.
    • 06 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top